I was curious what approaches the DOJ/PTO briefs had taken in recent biotech section 101 cases. Here are links to the briefs by the DOJ in:
LabCorp v. Metabolite (Supreme Court): [Link]
The Association for Molecular Pathology et al. v. Myriad (Federal Circuit) (as you may recall the PTO did not join in this brief): [Link]
Mayo v. Prometheus (Supreme Court): [Link].